Diagnostic value of suPAR in differentiating noncardiac pleural effusions from cardiac pleural effusions.
INTRODUCTION
Soluble urokinase plasminogen activator receptor (suPAR) is a newly discovered inflammatory biomarker. suPAR has not been previously studied in differentiating noncardiac pleural effusion (PF) from cardiac PF. The aim of our study was to assess the diagnostic value of suPAR in PF.


METHODS
The concentration of PF-suPAR was measured by a commercialized enzyme-linked immunosorbent assay in a prospective cohort of 74 patients with PF, 18 patients with PF due to cardiac failure (CF) and 56 patients with noncardiac PF. The area under the curve quantified the overall diagnostic accuracy of the tests.


RESULTS
The median pleural fluid suPAR level was found as 23 (5.4-102.8) ng/mL. The median PF-suPAR level in CF was significantly lower than that of noncardiac effusions [11.8 (5.4-28.9) ng/mL vs 26.7 (8.2-102.8) ng/mL, respectively, P < 0.001]. The area under the receiver operating characteristic curve was 0.878 (95% confidence interval: 0795-0.962, P < 0.001) for noncardiac pleural fluid suPAR. The sensitivity, specificity and positive predictive value of PF-suPAR for noncardiac effusions at the cutoff level of ≥17.6 n/mL was 88%, 83% and 94%, respectively. The suPAR level in PF was found to correlate with all of the biochemical parameters of PF.


CONCLUSIONS
suPAR is a potential new marker for the discrimination between cardiac and noncardiac PF.
['Ozsu|Savas|S|', 'Oztuna|Funda|F|', 'Mentese|Ahmet|A|', 'Abul|Yasin|Y|', 'Ozlu|Tevfik|T|']
D000293:Adolescent D000328:Adult D000368:Aged D000369:Aged, 80 and over D015415:Biomarkers D003937:Diagnosis, Differential D005260:Female D006801:Humans D008297:Male D008875:Middle Aged D010996:Pleural Effusion D016066:Pleural Effusion, Malignant D011237:Predictive Value of Tests D011446:Prospective Studies D055293:Receptors, Urokinase Plasminogen Activator
pleural effusion soluble urokinase plasminogen activator receptor diagnosis